Evidence map›Paper›PMID 40114891›Full record

ArticleIndian journal of surgical oncology2025

Oncological Outcomes in Patients with Delayed Cytoreductive Surgery During COVID Times.

Debabrata Barmon, Eshwarya Jessy Kaur, Upasana Baruah, Dimpy Begum, Partha Sarthi Roy, Duncan Khanikar, Mouchumee Bhattacharyya, Shiraj Ahmed, Mahendra Kumar, Sharda Patra and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Debabrata BarmonDepartment of Gynaecological Oncology, Dr B Borooah Cancer Institute, Tata Memorial Hospital, Guwahati, India.
Eshwarya Jessy KaurDepartment of Obstetrics and Gynaecology, Command Hospital, Lucknow, India 226002.ORCID 0000-0003-1837-0336
Upasana BaruahDepartment of Gynaecological Oncology, Dr B Borooah Cancer Institute, Tata Memorial Hospital, Guwahati, India.
Dimpy BegumDepartment of Gynaecological Oncology, Dr B Borooah Cancer Institute, Tata Memorial Hospital, Guwahati, India.
Partha Sarthi RoyDepartment of Medical Oncology, Dr B Borooah Cancer Institute, Tata Memorial Hospital, Guwahati, India.
Duncan KhanikarDepartment of Medical Oncology, Dr B Borooah Cancer Institute, Tata Memorial Hospital, Guwahati, India.
Mouchumee BhattacharyyaDepartment of Radiation Oncology, Dr B Borooah Cancer Institute, Tata Memorial Hospital, Guwahati, India.
Shiraj AhmedDepartment of Oncopathology, Dr B Borooah Cancer Institute, Tata Memorial Hospital, Guwahati, India.
Mahendra KumarDepartment of Gynaecological Oncology, Dr B Borooah Cancer Institute, Tata Memorial Hospital, Guwahati, India.
Sharda PatraDepartment of Obstetrics and Gynaecology, Lady Hardinge Medical College, Delhi, India.
Ratnadeep SharmaDr B Borooah Cancer Institute, Tata Memorial Hospital, Guwahati, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ESMO ESGO guidelines recommend standard 3-4 cycles of neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancers (EOC); however, the ideal number of cycles is still debatable. Literature regarding survival after 5 or more cycles is conflicting. COVID pandemic saw several oncosurgeries postponed due to healthcare crises. The present study was undertaken to evaluate oncological outcomes in patients undergoing delayed cytoreductive surgery (CRS) in advanced Epithelial Ovarian Cancer. This was a hospital-based, retrospective, observational study done at tertiary cancer institute. Objectives were to evaluate progression free survival (PFS) and overall survival (OS) according to timing of surgery and to identify prognostic factors for OS and PFS. The study group included patients undergoing delayed CRS (defined as CRS done after more than 5 cycles of NACT), and the control group is comprised of CRS done after 3-4 cycles NACT. A total of 29 patients underwent delayed CRS. Of these, 58% (

Indexed as

Cytoreductive surgeryEpithelial ovarian cancerNeoadjuvant chemotherapyOvarian cancer survival

Identifiers

PMID40114891
PMCPMC11920554

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.